Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from M.M. Regan et al have provided new data on breast cancer
August 14th, 2008
"The role of chemotherapy in addition to combined endocrine therapy for premenopausal women with endocrine-responsive early breast cancer remains an open question, yet trials designed to answer it have repeatedly failed to adequately accrue. The International Breast Cancer Study Group initiated two concurrent trials in this population: in Premenopausal Endocrine Responsive Chemotherapy (PERCHE), chemotherapy use is determined by randomization and in Tamoxifen and Exemestane Trial (TEXT) by physician choice," scientists in Bern, Switzerland report. "PERCHE closed with inadequate accrual; TEXT accrued rapidly. From 2003 to 2006, 1317 patients (890 with baseline data) were...
Source: Women's Health Weekly (2008-08-14)
|
